Etiology and pathogenesis of Parkinson's disease: role of mitochondrial pathology

Ottolini, Denis; Calì, Tito; Brini, Marisa
May 2013
Research & Reports in Biochemistry;May2013, Vol. 3, p55
Academic Journal
Neurons critically rely on mitochondrial activity: they are characterized by high energy demand and they are totally dependent on the process of oxidative phosphorylation to produce adenosine triphosphate. Thus, any impairment in mitochondrial function results in neuronal damage and degeneration. Some particular neuronal populations are more susceptible to mitochondrial damage, as it has been recently proposed for the ventral midbrain dopaminergic neurons, the degeneration of which represents a clinical sign of Parkinson's disease. Different cellular pathways are involved in the pathogenesis of this neurodegenerative disease, but intriguingly both sporadic and familial forms share common features that essentially recapitulate mitochondrial dysfunction. Mitochondrial biogenesis, bioenergetics, mitochondria dynamics, and quality-control process are the main affected pathways. General consensus agrees on the possibility that deficiency in these processes may represent the cause rather than the consequence of neurodegeneration. In this review, we will discuss these aspects and the substantial achievements that have been reached in recent years in identifying specific defects in precise biological processes, eg, mitochondrial quality control. The development of cell and animal genetic models has been an important tool to dissect numerous molecular details; for this reason, we will mainly refer to experiments performed on them.


Related Articles

  • Releasing the nerve cell killers. Welch, Kevin; Yuan, Junying // Nature Medicine;Jun2002, Vol. 8 Issue 6, p564 

    Attempts to find how a-synuclein functions and how it contributes to neurodegeneration since intracellular protein aggregates containing a-synuclein are hallmarks of neurodegenerative disorders like Parkinson disease (PD). Result of interaction of a-synuclein and dopamine in dopaminergic...

  • Glutamate Receptors and Parkinson’s Disease: Opportunities for Intervention. Marino, Michael J.; Valenti, Ornella; Conn, P. Jeffrey // Drugs & Aging;2003, Vol. 20 Issue 5, p377 

    Parkinson’s disease is a debilitating neurodegenerative movement disorder that is the result of a degeneration of dopaminergic neurons in the substantia nigra pars compacta. The resulting loss of striatal dopaminergic tone is believed to underlie a series of changes in the circuitry of...

  • The role of mitochondria in neurodegenerative diseases. Filosto, Massimiliano; Scarpelli, Mauro; Cotelli, Maria; Vielmi, Valentina; Todeschini, Alice; Gregorelli, Valeria; Tonin, Paola; Tomelleri, Giuliano; Padovani, Alessandro // Journal of Neurology;Oct2011, Vol. 258 Issue 10, p1763 

    Mitochondria are implicated in several metabolic pathways including cell respiratory processes, apoptosis, and free radical production. Mitochondrial abnormalities have been documented in neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's diseases, and amyotrophic...

  • Parkinson's Disease Update.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p6 

    The article reports update on the treatment of Parkinson's disease. Scientists from Universite Laval's Faculty of Medicine in Quebec have succeeded in producing neurons in vitro using stem cells extracted from adult human skin. The said discovery could lead to revolutionary advances in the...

  • D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinson's Disease. Lewis, M. M.; Huang, X.; Nichols, D. E.; Mailman, R. B. // CNS & Neurological Disorders - Drug Targets;2006, Vol. 5 Issue 3, p345 

    Parkinson's disease (PD) is a progressive neurodegenerative disorder that results in major motor disturbances due primarily to loss of midbrain dopamine neurons. The mainstream treatment has been dopaminergic replacement therapy aimed at symptomatic relief, with the gold standard drug being the...

  • Genome-wide association studies: the key to unlocking neurodegeneration? Gandhi, Sonia; Wood, Nicholas W. // Nature Neuroscience;Jul2010, Vol. 13 Issue 7, p789 

    The successful discovery of genes that cause rare monogenic disorders has dominated our understanding of the genetic basis of neurodegenerative disease. The emergence of robust genome-wide association methodologies promises to explain the genetic etiology of the common sporadic forms of complex...

  • Functional genomics approaches to neurodegenerative diseases. Rubinsztein, David C. // Mammalian Genome;Sep2008, Vol. 19 Issue 9, p587 

    Many of the neurodegenerative diseases that afflict humans are characterised by the protein aggregation in neurons. These include complex diseases like Alzheimer�s disease and Parkinson�s disease, and Mendelian diseases caused by polyglutamine expansion mutations [like...

  • Genetic Dissection of Strain Dependent Paraquatinduced Neurodegeneration in the Substantia Nigra Pars Compacta. Yun Jiao; Lu Lu; Williams, Robert W.; Smeyne, Richard J. // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The etiology of the vast majority of Parkinson's disease (PD) cases is unknown. It is generally accepted that there is an interaction between exposures to environmental agents with underlying genetic sensitivity. Recent epidemiological studies have shown that people living in agricultural...

  • Mitochondrial Dysfunction and Molecular Bases of Neurodegenerative Diseases. Kolesnikova, E. // Neurophysiology;Jan2013, Vol. 45 Issue 1, p89 

    This paper reviews the published data of modern studies, which allow one to summarize the accumulated knowledge on the molecular mechanisms underlying the development of some neurodegenerative diseases and the role of disorders of these mechanisms in the pathogenesis of diseases directly related...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics